Medicamen Biotech Secures USFDA Approval for Bortezomib Injection, Strengthening Oncology Portfolio

Unknown Apr 02, 2026 1,050 Views

Medicamen Biotech Ltd. has successfully received Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (USFDA) for Bortezomib for Injection 3.5 mg, marking a significant milestone in its oncology drug portfolio. The approval is expected to boost the company&rsq...